# Spyre Therapeutics (SYRE) — Earnings

SYRE · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/syre/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2025 |
| Period end | Jun 30, 2025 |
| EPS actual | −$0.49 |
| EPS estimate | −$0.75 |
| EPS surprise | +34.98% |
| Revenue surprise | +0.00% |
| Revenue | $0.00 |
| Revenue estimate | $0.00 |
| Reported | Aug 5, 2025 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1636282/000163628225000089/syre-20250630.htm) |

Spyre Therapeutics' most recent results in the table are for Q2 2025, reported on August 5, 2025. It posted a loss of $0.49 per share, narrower than the expected loss of $0.75, a 34.98% beat. No revenue was reported and no revenue estimate was given. A year earlier, in Q2 2024, the loss was $0.86 per share.

Every one of the 20 quarters in the table, back to Q3 2020, was a loss. Per-share losses were much larger in earlier years: annual losses were $25.00 per share in 2021, $25.33 in 2022 and $75.14 in 2023, with the largest single quarter at a $56.75 loss in Q2 2023. The 2024 annual loss was $4.23 per share, and the first half of 2025 came to $1.09, against $2.06 in the first half of 2024. Revenue was small and is missing from Q3 2023 onward. Spyre beat the EPS estimate in 9 of the 20 quarters, including the last three.

The table has no quarter after Q2 2025. In past years, third-quarter results came in early November and fourth-quarter results between late February and mid-March. Newer quarters will show whether the per-share loss keeps narrowing.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2025 | Aug 5, 2025 | −$0.75 | −$0.49 | 34.98% | — | — |
| Q1 2025 | May 8, 2025 | −$0.84 | −$0.60 | 28.66% | — | — |
| Q4 2024 | Feb 27, 2025 | −$0.99 | −$0.81 | 17.86% | $3.0M | — |
| Q3 2024 | Nov 7, 2024 | −$0.82 | −$1.36 | -64.99% | — | — |
| Q2 2024 | Aug 7, 2024 | −$0.95 | −$0.86 | 9.45% | $6.7M | — |
| Q1 2024 | May 9, 2024 | −$1.05 | −$1.20 | -14.41% | — | — |
| Q4 2023 | Feb 29, 2024 | −$0.73 | −$4.05 | -456.93% | $371,333.00 | — |
| Q3 2023 | Nov 9, 2023 | −$0.60 | −$9.34 | -1456.67% | $198,000.00 | — |
| Q2 2023 | Aug 11, 2023 | −$3.48 | −$56.75 | -1528.55% | $198,000.00 | $688,000.00 |
| Q1 2023 | May 11, 2023 | −$4.50 | −$5.00 | -11.11% | $184,000.00 | $198,000.00 |
| Q4 2022 | Mar 2, 2023 | −$5.71 | −$5.00 | 12.41% | $133,333.00 | $168,000.00 |
| Q3 2022 | Nov 3, 2022 | −$6.25 | −$4.33 | 30.79% | $208,333.00 | $174,000.00 |
| Q2 2022 | Aug 4, 2022 | −$7.95 | −$6.75 | 15.05% | $709,500.00 | $625,000.00 |
| Q1 2022 | May 5, 2022 | −$8.54 | −$9.25 | -8.37% | $1.6M | $1.4M |
| Q4 2021 | Mar 8, 2022 | −$7.19 | −$7.75 | -7.83% | $3.7M | $3.6M |
| Q3 2021 | Nov 4, 2021 | −$6.98 | −$7.75 | -11.03% | $4.0M | $1.4M |
| Q2 2021 | Aug 5, 2021 | −$4.11 | −$2.50 | 39.15% | $12.2M | $13.7M |
| Q1 2021 | May 10, 2021 | −$5.71 | −$7.00 | -22.50% | $8.7M | — |
| Q4 2020 | Mar 18, 2021 | −$7.68 | −$8.75 | -13.95% | — | — |
| Q3 2020 | Nov 5, 2020 | −$9.79 | −$7.25 | 25.97% | — | — |

## Frequently Asked Questions

### When did Spyre Therapeutics (SYRE) last report earnings?

Spyre Therapeutics last reported on Aug 5, 2025, covering fiscal Q2 2025.

### Did SYRE beat earnings estimates?

Yes. Spyre Therapeutics reported EPS of −$0.49 for Q2 2025 against a −$0.75 estimate — a 34.98% beat.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).